A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune system. It essentially hacks the immune cells, transferring its own faulty mitochondrial DNA (mtDNA) into the T-cells meant to …
An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating a common and challenging form of cancer called diffuse larg…
New research highlights the promise of a novel stem cell treatment strategy for leptomeningeal brain metastasis (LBM), a severe form of metastatic brain cancer that spreads to membranes surrounding the brain and spinal cord and occurs in up to 20% of p…
A research team at the Medical University of Vienna led by Maria Sibilia has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiqu…
The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Although neoadjuvant chemotherapy together with immunotherapy has been approved for advanced TNBC,…
UK oncology researchers have come together to write the first-ever national thought leadership strategy report into cancer vaccine advances and the opportunities these present for those affected by cancer. The strategy report has been published in the …
Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14%.
A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.
Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, is strongly induced in CD8+ T cells in solid cancer, the primary immune cells involved in combating cancer. P4HA1 causes disrup…
